© Eurofins expands with diagnostics for rare diseases
in the U.S.

September 2015. Emory Genetics Laboratory operates since July 10, 2015 as independent registered company (EGL Genetic Diagnostics LLC). Sole manager is Jack Tillman affiliated to Emory Innovations Inc., which is the commercialization arm of the Georgian university. EGL is a spin-off from the university’s Human Genetics Department/Division of Medical Genetics (Drs. Yuan Xue, Madhuri Hegde). In recent years EGL has sought to expand to Europe with diagnostic services for rare genetic disorders (e.g. autism, muscular dystrophy, rare cancers), but had to realise that without a touchbase on the other side of the Atlantic it could hardly compete with well-implanted human genetics services organised as non-profit / for-profit hybrids like Genome Diagnostics Nijmegen; MicroArray Facility Tübingen, or Life & Brain Bonn). The acquisition of EGL enables Eurofins to strengthen its U.S. biopharm services with diagnostic testing services for rare genetic diseases.

For decades this has been the (profitable) domain of specialised doctors’ practice, clinical laboratories in large university centres and powerful independent patient organisations like Association Française des Myopathies (see Kroner 2003). Today, the niche rapidly expands with novel technologies like point-of-care microfluidics (Feiglin 2014) or clinical next-generation sequencing (Hood 2012). Data derived from clinical routine drives pharma research. Genotyping regularly reveals rare disorders to be crucially involved in common disease mechanisms. And this, in turn, spurs the interest of pharmaceutical companies and demand for corresponding testing services. However, sampling and interpretation of result require special expertise in medical genetics – the reason why Eurofins is operating Eurofins Medigenomix (a spin-off from stock-listed German Medigene AG) in Europe and now acquired Emory Genetics in the United States. ed.


Food and Drug Administration (2015): Rare Diseases – Common Issues in Drug Development Guidance for Industry. Rockville, July 29.

Kroner WG (2003): eHealth for Rare Diseases – Markets, Providers and Trends. (in German). Journal medizinischegenetik 15: 11-21.

Feiglin M (2014): Diagnostic Microfluidics: Sample In, Results Out? B2Bioworld May.

Hood L (2012): Metrics for Disease, Health, and Wellness. A System Look. B2Bioworld, November.

Comment on company press release
01-09-2015. Eurofins announces the successful closing of the acquisition of a controlling stake in Emory Genetics Laboratory

Copyright Notice
Please note: You may freely distribute the link to this article. Any copying, distributing, or publishing of the entire article or parts of it (picture included) requires prior written consent by B2Bioworld or by third parties retaining copyrights. All rights reserved.

This editorial article is brought to you free of charge. You may see how we work, investigate issues,
and write up results in articles free of advertising and normally at cost . Enjoy reading

Back to section

Other Articles Recommended

B2Bioworld offers you background information

Make or Break Drug Discovery and Biopharma of Merck Life Science
Andrew Bulpin, Global Head of Merck Millipore Process Solutions  on strategy and the road ahead

Thermo Fisher’s BRIMS-strategy under Testing

Eurofins: Sustainable profitability – albeit not for investors in a hurry

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

Eurofins helps Pasteur de Lille out of the doldrums
Prospects of IPL’s analytical services business

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities

The Myriad Way
Peter D Meldrum, past CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Patient-centered Precision Care
Michael Christman, President of Coriell Institute about turning research on human genotyping into healthcare routine